Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Two data releases at London Valves 2024 build on Evolut’s legacy of valve design and performance: Optimize PRO study demonstrates improved procedure efficiencies and valve performance Pooled...
Additional GI Genius™ units installed at VA facilities, providing enhanced colonoscopy care and advancing AI-powered diagnostics for veterans
Endoflip™ is an advanced diagnostic tool that can help expedite accurate diagnosis of esophageal motility disorders, conditions often missed during endoscopies.1,2
Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies
With its Meal Detection Technology™* and autocorrections every 5 minutes, Medtronic is expanding outcomes to populations in Asia and empowering patients to achieve greater glycemic control, especially during mealtimes.
New data from Australia, Japan, India, Singapore, Hong Kong, and South Korea demonstrates the MiniMed™ 780G is driving consistent clinical outcomes in diabetes management.
Comparative data and systematic literature review released at VIVA 2024 show breadth and depth of data supporting atherectomy as a treatment for peripheral arterial disease
Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access
Funding to support organisations with a mission to improve health outcomes
The VT research will provide important clinical evidence in an underserved patient population
Survey of 1,000 U.S. surgeons finds digital tech like AI and live streaming crucial to closing surgical care gaps in under-resourced regions.
Global expansion of the Avalus Ultra valve continues in Western Europe while company highlights robust, innovative Cardiac Surgery portfolio at EACTS in Lisbon
Bolsters Medtronic Cardiac Surgery’s comprehensive portfolio of cardiac surgical and respiratory innovation
Company recognized among top 52 global companies making positive social impact through core business strategy
ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease
Dr. James Porter will represent the company this week — including from the Hugo™ console to perform a live partial nephrectomy — at Europe’s biggest urology conference
Annual award celebrates companies fostering cultures of innovation
State-of-the-art facility based in Singapore aims to accelerate adoption of Robotics and AI across Southeast Asia through training and education, improving access to new healthcare technologies and delivering better care experiences across the region
The company will present clinical evidence in young children, pregnancy and type 2 diabetes*